Clinical Effectiveness of Sevoflurane in Dogs. Comparative Study with Isoflurane
WSAVA 2002 Congress
*Gomez-Villamandos, RJ, Villalobos, CM, Granados, MM, Domínguez, JI, Ruiz, I, Santisteban, JM
*Dept. Medicina y Cirugía Animal. Universidad de Córdoba, Campus Universitario de Rabanales
Córdoba, ES
pv1govir@uco.es

OBJECTIVES

Sevoflurane is an inhalant volatile anaesthetic that has been recently introduced in veterinary medicine. The advantages of sevoflurane in domestic animals have been reported in several experimental studies. The aim of this study was determine clinical effectiveness of sevoflurane in dogs with different anaesthetic risk.

MATERIALS

A total of 307 dogs (144 males and 163 females, age 3.5±3.2 years and weighing 19.3±9.7 Kg) were included in this study. 157 dogs (107 ASAI, 32 ASAII, 12 ASAIII and 5 ASAIV) were anaesthetized with sevoflurane, and 150 patients (87 ASAI, 40 ASAII, 17 ASAIII and 6 ASAIV) with isoflurane. Alfa-2 adrenoceptor agonist sedatives (medetomidine at 5-10 mg/kg IV, or romifidine at 20-40 mg/kg IV) were used as preanesthetic in all cases to exception ASAIV patients. Anaesthesia was induced with propofol (2 mg/kg IV). After tracheal intubation anaesthesia was maintenance with sevoflurane or isoflurane in oxygen via a semiclosed circuit. The following variables were registered: Heart rate (HR), respiratory rate (RR), mean arterial pressure (MAP), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), hemoglobin oxygen saturation (SpO2), end-tidal carbon dioxide (EtCO2), tidal volume (VT), end-tidal sevoflurane and isoflurane concentrations (EtSEV, EtISO). RR, VT, EtCO2, EtSEV and EtISO were recorded with a respiratory gases monitor (RGM-5250, Ohmeda-Boc). HR, MAP, SAP, DAP and SpO2 were registered with a cardiovascular monitor (Dinamap Plus 8720, Critikon Inc). Recovery times also were registered. Statistical analysis was performed using an ANOVA and a post hoc test (Tukey HSD for unequal N). Values were considered significant when p<0.05.

RESULTS

HR, RR, SpO2 and recovery times no showed differences between sevoflurane and isoflurane. MAP, SAP and DAP were higher during sevoflurane anaesthesia. EtCO2 and VT were lower during isoflurane anaesthesia. These differences were also registered for each anaesthetic risk. The mean EtSEV and EtISO values were 2.1±0.5% and 1.4±.0.4% respectively.

CONCLUSION

Results suggest that sevoflurane anesthesia provide a better cardiovascular and respiratory stability.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

JI DOMÍNGUEZ
Universidad de Córdoba

R J GOMEZ-VILLAMANDOS
Dept. Medicina y Cirugía Animal. Universidad de Córdoba
Campus Universitario de Rabanales
Córdoba, Córdoba 14014-Córdoba ES

M M GRANADOS
Universidad de Córdoba

I RUIZ
Universidad de Córdoba

J M SANTISTEBAN
Universidad de Córdoba

C M VILLALOBOS
Universidad de Córdoba


MAIN : : Sevoflurane in Dogs
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27